Physician profile
David V Pulliam
NPI 1417915372
$1,045.24
in general payments reported to CMS, 2019-2025
25 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $77.44 · 2021: $93.14 · 2022: $151 · 2023: $102 · 2024: $95.69 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155.65 | 2019-2024 | Wegovy |
| Amgen INC. | $134.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $132.17 | 2020-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $59.69 | 2019-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $50.86 | 2019 | |
| Melinta Therapeutics, LLC | $49.19 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.88 | 2022 | |
| Sanofi-Aventis U.S. LLC | $40.55 | 2021 | |
| Abbvie INC. | $39.47 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $35.17 | 2019 | |
| Sequel Med Tech, LLC | $34.61 | 2025 | Twiist |
| Pfizer INC. | $32.70 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $32.03 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $29.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.05 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.19 | 2025 | Eliquis |
| Exact Sciences Corporation | $17.14 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $16.01 | 2019 | |
| Insulet Corporation | $15.77 | 2021 | |
| Abbott Laboratories | $15.60 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.11 | 2020 | |
| Lilly USA, LLC | $13.46 | 2023 | Trulicity, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $13.00 | 2022 | |
| Mylan Specialty L.P. | $11.51 | 2019 | |
| Endogastric Solutions, INC | $7.48 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pulliam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.